---
title: "Frontier Biotechnologies Inc. (688221.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688221.SH.md"
symbol: "688221.SH"
name: "Frontier Biotechnologies Inc."
industry: "Biotechnology"
datetime: "2026-05-20T00:25:16.974Z"
locales:
  - [en](https://longbridge.com/en/quote/688221.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688221.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688221.SH.md)
---

# Frontier Biotechnologies Inc. (688221.SH)

## Company Overview

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.frontierbiotech.com](https://www.frontierbiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.36)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 13 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 194.54% |  |
| Net Profit YoY | 101.82% |  |
| P/B Ratio | 7.45 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8244087811.06 |  |
| Revenue | 391815699.32 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.31% | D |
| Profit Margin | 0.88% | C |
| Gross Margin | 94.01% | A |
| Revenue YoY | 194.54% | A |
| Net Profit YoY | 101.82% | A |
| Total Assets YoY | 7.35% | B |
| Net Assets YoY | 1.01% | C |
| Cash Flow Margin | 1154.19% | A |
| OCF YoY | 194.54% | A |
| Turnover | 0.22 | D |
| Gearing Ratio | 40.11% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Frontier Biotechnologies Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "194.54%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "101.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.45",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8244087811.06",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "391815699.32",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.31%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.88%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "94.01%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "194.54%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "101.82%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.35%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.01%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1154.19%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "194.54%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.11%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 2409.38 | 45/81 | 2468.89 | 2409.38 | 2264.41 |
| PB | 7.53 | 64/81 | 7.79 | 6.96 | 5.18 |
| PS (TTM) | 21.27 | 70/81 | 56.24 | 49.08 | 37.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-08T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.27 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688221.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688221.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688221.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**